公司资料
TransMedics 股价、新闻与催化剂
- 股票代码:
- TMDX
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
78.64 USD (-5.76%)
收盘价
最后更新: 2026年10月1日
2.37B USD
市值
股价为何变动
截至 2026年10月1日，TMDX 下跌 5.76%，收于 $78.64。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
Organ Transplant Technology Company
TransMedics develops technology and services intended to expand access to donor organs for patients with end-stage heart, lung, and liver failure.
Organ Care System
The Organ Care System uses portable extracorporeal warm perfusion to preserve donor organs in a functioning state outside the body. The platform also allows clinicians to assess organ condition before transplantation.
Heart, Lung, and Liver Applications
Separate OCS configurations support donor hearts, lungs, and livers. The technology is designed to reduce the limitations of static cold storage and enable the use of organs that might otherwise be declined.
National OCS Program
The National OCS Program provides a coordinated service that includes trained clinical specialists, logistics, and OCS deployment. This turnkey model helps transplant centers access the technology without building every operational capability internally.
Integrated Aviation and Development Pipeline
TransMedics is building dedicated aviation and logistics capacity in the United States and Europe to transport organs and clinical teams. Development investments include OCS Kidney, next-generation OCS technology, and clinical programs intended to expand the platform.
未来催化剂
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。